CMD

CMD Bioscience is a private computational biotechnology company focused on peptide drug discovery for pharmaceutical, biotech, and life science partners. Its core asset is CMDInventus, a proprietary in silico platform used to model protein-protein and protein-peptide interactions, identify peptide hits, and optimize leads. The company has described both partnered discovery work and wholly owned peptide programs, with disclosed oncology efforts in hematologic malignancies such as leukemia and lymphoma. Publicly available information suggests the business is platform-driven and remains at a preclinical stage rather than a clinical-stage therapeutics company. The company also appears to offer computational discovery services and related research products through its website.